nodes	percent_of_prediction	percent_of_DWPC	metapath
Docetaxel—head and neck cancer—esophageal cancer	0.13	0.313	CtDrD
Docetaxel—stomach cancer—esophageal cancer	0.106	0.256	CtDrD
Docetaxel—pancreatic cancer—esophageal cancer	0.0992	0.239	CtDrD
Docetaxel—NR1I2—esophageal cancer	0.0853	0.281	CbGaD
Docetaxel—lung cancer—esophageal cancer	0.0801	0.193	CtDrD
Docetaxel—BCL2—esophageal cancer	0.0707	0.233	CbGaD
Docetaxel—CYP1B1—esophageal cancer	0.049	0.161	CbGaD
Docetaxel—EGFR—esophageal cancer	0.0462	0.152	CbGaD
Docetaxel—ABCC2—esophageal cancer	0.0382	0.126	CbGaD
Docetaxel—ABCC10—Methotrexate—esophageal cancer	0.0274	0.199	CbGbCtD
Docetaxel—SLCO1B3—Methotrexate—esophageal cancer	0.0153	0.111	CbGbCtD
Docetaxel—ABCC2—Carboplatin—esophageal cancer	0.0141	0.102	CbGbCtD
Docetaxel—ABCB1—esophageal cancer	0.0141	0.0463	CbGaD
Docetaxel—SLC22A7—Methotrexate—esophageal cancer	0.0135	0.0976	CbGbCtD
Docetaxel—ABCG2—Carboplatin—esophageal cancer	0.0128	0.0925	CbGbCtD
Docetaxel—ABCC2—Cisplatin—esophageal cancer	0.0121	0.0874	CbGbCtD
Docetaxel—ABCG2—Cisplatin—esophageal cancer	0.0109	0.079	CbGbCtD
Docetaxel—ABCC1—Methotrexate—esophageal cancer	0.0106	0.0767	CbGbCtD
Docetaxel—ABCC2—Methotrexate—esophageal cancer	0.00784	0.0567	CbGbCtD
Docetaxel—ABCG2—Methotrexate—esophageal cancer	0.00709	0.0513	CbGbCtD
Docetaxel—ABCB1—Cisplatin—esophageal cancer	0.00394	0.0285	CbGbCtD
Docetaxel—ABCB1—Methotrexate—esophageal cancer	0.00256	0.0185	CbGbCtD
Docetaxel—KIF11—lung—esophageal cancer	0.000839	0.0372	CbGeAlD
Docetaxel—BCL2—neck—esophageal cancer	0.000813	0.036	CbGeAlD
Docetaxel—NR1I2—digestive system—esophageal cancer	0.000707	0.0313	CbGeAlD
Docetaxel—MAP2—neck—esophageal cancer	0.000704	0.0312	CbGeAlD
Docetaxel—Paclitaxel—NR1I2—esophageal cancer	0.000636	0.275	CrCbGaD
Docetaxel—KIF11—lymph node—esophageal cancer	0.000574	0.0254	CbGeAlD
Docetaxel—BCL2—epithelium—esophageal cancer	0.000553	0.0245	CbGeAlD
Docetaxel—BCL2—smooth muscle tissue—esophageal cancer	0.000533	0.0236	CbGeAlD
Docetaxel—Paclitaxel—BCL2—esophageal cancer	0.000527	0.228	CrCbGaD
Docetaxel—MAP2—bronchus—esophageal cancer	0.000472	0.0209	CbGeAlD
Docetaxel—TUBB3—digestive system—esophageal cancer	0.000463	0.0205	CbGeAlD
Docetaxel—MAP4—digestive system—esophageal cancer	0.000463	0.0205	CbGeAlD
Docetaxel—MAP2—trachea—esophageal cancer	0.000424	0.0188	CbGeAlD
Docetaxel—BCL2—digestive system—esophageal cancer	0.000421	0.0186	CbGeAlD
Docetaxel—TUBB3—lung—esophageal cancer	0.000387	0.0171	CbGeAlD
Docetaxel—MAP4—lung—esophageal cancer	0.000387	0.0171	CbGeAlD
Docetaxel—Paclitaxel—CYP1B1—esophageal cancer	0.000365	0.158	CrCbGaD
Docetaxel—MAP2—digestive system—esophageal cancer	0.000364	0.0161	CbGeAlD
Docetaxel—TUBB2B—bronchus—esophageal cancer	0.000352	0.0156	CbGeAlD
Docetaxel—BCL2—lung—esophageal cancer	0.000351	0.0156	CbGeAlD
Docetaxel—EGFR—lung—esophageal cancer	0.000347	0.0154	CbGeAlD
Docetaxel—SLCO1B3—lung—esophageal cancer	0.000338	0.015	CbGeAlD
Docetaxel—MAPT—lymph node—esophageal cancer	0.000336	0.0149	CbGeAlD
Docetaxel—TUBB—bronchus—esophageal cancer	0.000333	0.0148	CbGeAlD
Docetaxel—TUBB6—epithelium—esophageal cancer	0.000332	0.0147	CbGeAlD
Docetaxel—TUBB2A—bronchus—esophageal cancer	0.000332	0.0147	CbGeAlD
Docetaxel—TUBB6—bronchus—esophageal cancer	0.000327	0.0145	CbGeAlD
Docetaxel—TUBB—smooth muscle tissue—esophageal cancer	0.000326	0.0145	CbGeAlD
Docetaxel—TUBB2A—smooth muscle tissue—esophageal cancer	0.000325	0.0144	CbGeAlD
Docetaxel—TUBB6—smooth muscle tissue—esophageal cancer	0.00032	0.0142	CbGeAlD
Docetaxel—TUBB2B—trachea—esophageal cancer	0.000316	0.014	CbGeAlD
Docetaxel—SLC22A7—digestive system—esophageal cancer	0.000315	0.014	CbGeAlD
Docetaxel—MAP2—lung—esophageal cancer	0.000304	0.0135	CbGeAlD
Docetaxel—TUBB—trachea—esophageal cancer	0.000299	0.0133	CbGeAlD
Docetaxel—TUBB2A—trachea—esophageal cancer	0.000298	0.0132	CbGeAlD
Docetaxel—TUBB6—trachea—esophageal cancer	0.000294	0.013	CbGeAlD
Docetaxel—ABCC10—bronchus—esophageal cancer	0.000286	0.0127	CbGeAlD
Docetaxel—Paclitaxel—ABCC2—esophageal cancer	0.000285	0.123	CrCbGaD
Docetaxel—TUBB4B—bronchus—esophageal cancer	0.000284	0.0126	CbGeAlD
Docetaxel—TUBB4A—digestive system—esophageal cancer	0.000282	0.0125	CbGeAlD
Docetaxel—TUBB4B—smooth muscle tissue—esophageal cancer	0.000278	0.0123	CbGeAlD
Docetaxel—TUBB2B—digestive system—esophageal cancer	0.000272	0.0121	CbGeAlD
Docetaxel—Paclitaxel—CYP19A1—esophageal cancer	0.000268	0.116	CrCbGaD
Docetaxel—MAP4—lymph node—esophageal cancer	0.000264	0.0117	CbGeAlD
Docetaxel—ABCC10—trachea—esophageal cancer	0.000257	0.0114	CbGeAlD
Docetaxel—TUBB2A—digestive system—esophageal cancer	0.000256	0.0114	CbGeAlD
Docetaxel—TUBB4B—trachea—esophageal cancer	0.000255	0.0113	CbGeAlD
Docetaxel—TUBB6—digestive system—esophageal cancer	0.000253	0.0112	CbGeAlD
Docetaxel—BCL2—lymph node—esophageal cancer	0.00024	0.0106	CbGeAlD
Docetaxel—EGFR—lymph node—esophageal cancer	0.000237	0.0105	CbGeAlD
Docetaxel—TUBB4A—lung—esophageal cancer	0.000235	0.0104	CbGeAlD
Docetaxel—TUBB2B—lung—esophageal cancer	0.000227	0.0101	CbGeAlD
Docetaxel—ABCC10—digestive system—esophageal cancer	0.000221	0.0098	CbGeAlD
Docetaxel—CYP1B1—smooth muscle tissue—esophageal cancer	0.00022	0.00976	CbGeAlD
Docetaxel—TUBB4B—digestive system—esophageal cancer	0.00022	0.00973	CbGeAlD
Docetaxel—TUBB—lung—esophageal cancer	0.000215	0.00953	CbGeAlD
Docetaxel—TUBB2A—lung—esophageal cancer	0.000214	0.00948	CbGeAlD
Docetaxel—TUBB6—lung—esophageal cancer	0.000211	0.00935	CbGeAlD
Docetaxel—MAP2—lymph node—esophageal cancer	0.000208	0.00922	CbGeAlD
Docetaxel—ABCC1—bronchus—esophageal cancer	0.000203	0.00898	CbGeAlD
Docetaxel—ABCC10—lung—esophageal cancer	0.000185	0.00819	CbGeAlD
Docetaxel—TUBB4B—lung—esophageal cancer	0.000183	0.00813	CbGeAlD
Docetaxel—ABCC1—trachea—esophageal cancer	0.000182	0.00806	CbGeAlD
Docetaxel—ABCC2—digestive system—esophageal cancer	0.000178	0.00787	CbGeAlD
Docetaxel—CYP1B1—digestive system—esophageal cancer	0.000174	0.00771	CbGeAlD
Docetaxel—TUBB4A—lymph node—esophageal cancer	0.000161	0.00713	CbGeAlD
Docetaxel—TUBB2B—lymph node—esophageal cancer	0.000155	0.00689	CbGeAlD
Docetaxel—TUBB—lymph node—esophageal cancer	0.000147	0.00652	CbGeAlD
Docetaxel—TUBB2A—lymph node—esophageal cancer	0.000146	0.00648	CbGeAlD
Docetaxel—CYP1B1—lung—esophageal cancer	0.000145	0.00644	CbGeAlD
Docetaxel—TUBB6—lymph node—esophageal cancer	0.000144	0.0064	CbGeAlD
Docetaxel—ABCC1—lung—esophageal cancer	0.000131	0.00579	CbGeAlD
Docetaxel—Cabazitaxel—ABCB1—esophageal cancer	0.00013	0.056	CrCbGaD
Docetaxel—ABCC10—lymph node—esophageal cancer	0.000126	0.0056	CbGeAlD
Docetaxel—TUBB4B—lymph node—esophageal cancer	0.000125	0.00556	CbGeAlD
Docetaxel—CYP3A5—digestive system—esophageal cancer	0.00012	0.00533	CbGeAlD
Docetaxel—ABCG2—lung—esophageal cancer	0.000108	0.00479	CbGeAlD
Docetaxel—Paclitaxel—ABCB1—esophageal cancer	0.000105	0.0453	CrCbGaD
Docetaxel—ABCC2—lymph node—esophageal cancer	0.000101	0.0045	CbGeAlD
Docetaxel—CYP3A5—lung—esophageal cancer	0.0001	0.00445	CbGeAlD
Docetaxel—CYP1B1—lymph node—esophageal cancer	9.94e-05	0.0044	CbGeAlD
Docetaxel—Atrial fibrillation—Capecitabine—esophageal cancer	9.32e-05	0.00161	CcSEcCtD
Docetaxel—Renal impairment—Capecitabine—esophageal cancer	9.28e-05	0.00161	CcSEcCtD
Docetaxel—Dermatitis bullous—Capecitabine—esophageal cancer	9.24e-05	0.0016	CcSEcCtD
Docetaxel—Respiratory failure—Methotrexate—esophageal cancer	9.22e-05	0.0016	CcSEcCtD
Docetaxel—Acute coronary syndrome—Cisplatin—esophageal cancer	9.1e-05	0.00157	CcSEcCtD
Docetaxel—Renal failure—Cisplatin—esophageal cancer	9.08e-05	0.00157	CcSEcCtD
Docetaxel—Pulmonary embolism—Methotrexate—esophageal cancer	9.06e-05	0.00157	CcSEcCtD
Docetaxel—Myocardial infarction—Cisplatin—esophageal cancer	9.05e-05	0.00157	CcSEcCtD
Docetaxel—Neuropathy peripheral—Cisplatin—esophageal cancer	9.05e-05	0.00157	CcSEcCtD
Docetaxel—Cardiac failure—Capecitabine—esophageal cancer	9.05e-05	0.00157	CcSEcCtD
Docetaxel—CYP3A4—digestive system—esophageal cancer	9.03e-05	0.004	CbGeAlD
Docetaxel—Lethargy—Capecitabine—esophageal cancer	9.01e-05	0.00156	CcSEcCtD
Docetaxel—Stomatitis—Cisplatin—esophageal cancer	9e-05	0.00156	CcSEcCtD
Docetaxel—Conjunctivitis—Cisplatin—esophageal cancer	8.98e-05	0.00155	CcSEcCtD
Docetaxel—ABCC1—lymph node—esophageal cancer	8.94e-05	0.00396	CbGeAlD
Docetaxel—Hyponatraemia—Capecitabine—esophageal cancer	8.87e-05	0.00153	CcSEcCtD
Docetaxel—Pain in extremity—Capecitabine—esophageal cancer	8.83e-05	0.00153	CcSEcCtD
Docetaxel—Gastrointestinal haemorrhage—Capecitabine—esophageal cancer	8.83e-05	0.00153	CcSEcCtD
Docetaxel—Hepatobiliary disease—Cisplatin—esophageal cancer	8.73e-05	0.00151	CcSEcCtD
Docetaxel—Migraine—Capecitabine—esophageal cancer	8.69e-05	0.0015	CcSEcCtD
Docetaxel—Skin exfoliation—Methotrexate—esophageal cancer	8.65e-05	0.0015	CcSEcCtD
Docetaxel—ABCB1—epithelium—esophageal cancer	8.4e-05	0.00372	CbGeAlD
Docetaxel—Ataxia—Capecitabine—esophageal cancer	8.31e-05	0.00144	CcSEcCtD
Docetaxel—Dehydration—Capecitabine—esophageal cancer	8.21e-05	0.00142	CcSEcCtD
Docetaxel—Neoplasm—Methotrexate—esophageal cancer	8.19e-05	0.00142	CcSEcCtD
Docetaxel—Urinary tract disorder—Cisplatin—esophageal cancer	8.19e-05	0.00142	CcSEcCtD
Docetaxel—Liver function test abnormal—Capecitabine—esophageal cancer	8.16e-05	0.00141	CcSEcCtD
Docetaxel—Connective tissue disorder—Cisplatin—esophageal cancer	8.15e-05	0.00141	CcSEcCtD
Docetaxel—Urethral disorder—Cisplatin—esophageal cancer	8.13e-05	0.00141	CcSEcCtD
Docetaxel—Dry skin—Capecitabine—esophageal cancer	8.1e-05	0.0014	CcSEcCtD
Docetaxel—Abdominal pain upper—Capecitabine—esophageal cancer	8.07e-05	0.0014	CcSEcCtD
Docetaxel—Orthostatic hypotension—Capecitabine—esophageal cancer	8.07e-05	0.0014	CcSEcCtD
Docetaxel—Pulmonary oedema—Methotrexate—esophageal cancer	8.06e-05	0.00139	CcSEcCtD
Docetaxel—Visual impairment—Cisplatin—esophageal cancer	7.99e-05	0.00138	CcSEcCtD
Docetaxel—Breast disorder—Capecitabine—esophageal cancer	7.98e-05	0.00138	CcSEcCtD
Docetaxel—Toxic epidermal necrolysis—Capecitabine—esophageal cancer	7.95e-05	0.00138	CcSEcCtD
Docetaxel—Aspartate aminotransferase increased—Capecitabine—esophageal cancer	7.95e-05	0.00138	CcSEcCtD
Docetaxel—Nasopharyngitis—Capecitabine—esophageal cancer	7.9e-05	0.00137	CcSEcCtD
Docetaxel—Sepsis—Methotrexate—esophageal cancer	7.86e-05	0.00136	CcSEcCtD
Docetaxel—Alanine aminotransferase increased—Capecitabine—esophageal cancer	7.79e-05	0.00135	CcSEcCtD
Docetaxel—Eye disorder—Cisplatin—esophageal cancer	7.75e-05	0.00134	CcSEcCtD
Docetaxel—Flushing—Cisplatin—esophageal cancer	7.69e-05	0.00133	CcSEcCtD
Docetaxel—Cardiac disorder—Cisplatin—esophageal cancer	7.69e-05	0.00133	CcSEcCtD
Docetaxel—Dysphagia—Capecitabine—esophageal cancer	7.63e-05	0.00132	CcSEcCtD
Docetaxel—Thrombophlebitis—Methotrexate—esophageal cancer	7.6e-05	0.00131	CcSEcCtD
Docetaxel—Bronchospasm—Capecitabine—esophageal cancer	7.51e-05	0.0013	CcSEcCtD
Docetaxel—Immune system disorder—Cisplatin—esophageal cancer	7.49e-05	0.00129	CcSEcCtD
Docetaxel—Mediastinal disorder—Cisplatin—esophageal cancer	7.47e-05	0.00129	CcSEcCtD
Docetaxel—Angina pectoris—Capecitabine—esophageal cancer	7.44e-05	0.00129	CcSEcCtD
Docetaxel—ABCB1—trachea—esophageal cancer	7.43e-05	0.00329	CbGeAlD
Docetaxel—Arrhythmia—Cisplatin—esophageal cancer	7.41e-05	0.00128	CcSEcCtD
Docetaxel—ABCG2—lymph node—esophageal cancer	7.4e-05	0.00328	CbGeAlD
Docetaxel—Alopecia—Cisplatin—esophageal cancer	7.33e-05	0.00127	CcSEcCtD
Docetaxel—Hepatic failure—Methotrexate—esophageal cancer	7.32e-05	0.00127	CcSEcCtD
Docetaxel—Pancytopenia—Capecitabine—esophageal cancer	7.25e-05	0.00125	CcSEcCtD
Docetaxel—Erythema—Cisplatin—esophageal cancer	7.22e-05	0.00125	CcSEcCtD
Docetaxel—Malnutrition—Cisplatin—esophageal cancer	7.22e-05	0.00125	CcSEcCtD
Docetaxel—Neutropenia—Capecitabine—esophageal cancer	7.14e-05	0.00123	CcSEcCtD
Docetaxel—Weight increased—Capecitabine—esophageal cancer	6.95e-05	0.0012	CcSEcCtD
Docetaxel—Visual disturbance—Methotrexate—esophageal cancer	6.94e-05	0.0012	CcSEcCtD
Docetaxel—Muscle spasms—Cisplatin—esophageal cancer	6.94e-05	0.0012	CcSEcCtD
Docetaxel—Weight decreased—Capecitabine—esophageal cancer	6.91e-05	0.00119	CcSEcCtD
Docetaxel—Pneumonia—Capecitabine—esophageal cancer	6.85e-05	0.00118	CcSEcCtD
Docetaxel—Infestation NOS—Capecitabine—esophageal cancer	6.81e-05	0.00118	CcSEcCtD
Docetaxel—Infestation—Capecitabine—esophageal cancer	6.81e-05	0.00118	CcSEcCtD
Docetaxel—Stevens-Johnson syndrome—Capecitabine—esophageal cancer	6.75e-05	0.00117	CcSEcCtD
Docetaxel—Acute coronary syndrome—Capecitabine—esophageal cancer	6.71e-05	0.00116	CcSEcCtD
Docetaxel—Lethargy—Methotrexate—esophageal cancer	6.71e-05	0.00116	CcSEcCtD
Docetaxel—Renal failure—Capecitabine—esophageal cancer	6.69e-05	0.00116	CcSEcCtD
Docetaxel—Neuropathy peripheral—Capecitabine—esophageal cancer	6.67e-05	0.00115	CcSEcCtD
Docetaxel—Myocardial infarction—Capecitabine—esophageal cancer	6.67e-05	0.00115	CcSEcCtD
Docetaxel—Anaemia—Cisplatin—esophageal cancer	6.67e-05	0.00115	CcSEcCtD
Docetaxel—Jaundice—Capecitabine—esophageal cancer	6.64e-05	0.00115	CcSEcCtD
Docetaxel—Stomatitis—Capecitabine—esophageal cancer	6.64e-05	0.00115	CcSEcCtD
Docetaxel—Conjunctivitis—Capecitabine—esophageal cancer	6.62e-05	0.00114	CcSEcCtD
Docetaxel—Leukopenia—Cisplatin—esophageal cancer	6.46e-05	0.00112	CcSEcCtD
Docetaxel—Hepatobiliary disease—Capecitabine—esophageal cancer	6.44e-05	0.00111	CcSEcCtD
Docetaxel—Epistaxis—Capecitabine—esophageal cancer	6.42e-05	0.00111	CcSEcCtD
Docetaxel—ABCB1—digestive system—esophageal cancer	6.39e-05	0.00283	CbGeAlD
Docetaxel—Agranulocytosis—Capecitabine—esophageal cancer	6.35e-05	0.0011	CcSEcCtD
Docetaxel—Convulsion—Cisplatin—esophageal cancer	6.25e-05	0.00108	CcSEcCtD
Docetaxel—Ataxia—Methotrexate—esophageal cancer	6.18e-05	0.00107	CcSEcCtD
Docetaxel—Myalgia—Cisplatin—esophageal cancer	6.14e-05	0.00106	CcSEcCtD
Docetaxel—Haemoglobin—Capecitabine—esophageal cancer	6.14e-05	0.00106	CcSEcCtD
Docetaxel—Rhinitis—Capecitabine—esophageal cancer	6.13e-05	0.00106	CcSEcCtD
Docetaxel—Haemorrhage—Capecitabine—esophageal cancer	6.11e-05	0.00106	CcSEcCtD
Docetaxel—Hepatitis—Capecitabine—esophageal cancer	6.11e-05	0.00106	CcSEcCtD
Docetaxel—Unspecified disorder of skin and subcutaneous tissue—Cisplatin—esophageal cancer	6.1e-05	0.00106	CcSEcCtD
Docetaxel—Hypoaesthesia—Capecitabine—esophageal cancer	6.08e-05	0.00105	CcSEcCtD
Docetaxel—Liver function test abnormal—Methotrexate—esophageal cancer	6.07e-05	0.00105	CcSEcCtD
Docetaxel—Pharyngitis—Capecitabine—esophageal cancer	6.07e-05	0.00105	CcSEcCtD
Docetaxel—Urinary tract disorder—Capecitabine—esophageal cancer	6.03e-05	0.00104	CcSEcCtD
Docetaxel—Oedema peripheral—Capecitabine—esophageal cancer	6.02e-05	0.00104	CcSEcCtD
Docetaxel—Connective tissue disorder—Capecitabine—esophageal cancer	6.01e-05	0.00104	CcSEcCtD
Docetaxel—Urethral disorder—Capecitabine—esophageal cancer	5.99e-05	0.00104	CcSEcCtD
Docetaxel—Breast disorder—Methotrexate—esophageal cancer	5.94e-05	0.00103	CcSEcCtD
Docetaxel—Toxic epidermal necrolysis—Methotrexate—esophageal cancer	5.92e-05	0.00102	CcSEcCtD
Docetaxel—Anaphylactic shock—Cisplatin—esophageal cancer	5.89e-05	0.00102	CcSEcCtD
Docetaxel—Oedema—Cisplatin—esophageal cancer	5.89e-05	0.00102	CcSEcCtD
Docetaxel—Visual impairment—Capecitabine—esophageal cancer	5.89e-05	0.00102	CcSEcCtD
Docetaxel—Infection—Cisplatin—esophageal cancer	5.85e-05	0.00101	CcSEcCtD
Docetaxel—Erythema multiforme—Capecitabine—esophageal cancer	5.78e-05	0.000999	CcSEcCtD
Docetaxel—Nervous system disorder—Cisplatin—esophageal cancer	5.78e-05	0.000999	CcSEcCtD
Docetaxel—Thrombocytopenia—Cisplatin—esophageal cancer	5.77e-05	0.000997	CcSEcCtD
Docetaxel—Tachycardia—Cisplatin—esophageal cancer	5.75e-05	0.000994	CcSEcCtD
Docetaxel—Skin disorder—Cisplatin—esophageal cancer	5.72e-05	0.000989	CcSEcCtD
Docetaxel—Eye disorder—Capecitabine—esophageal cancer	5.71e-05	0.000988	CcSEcCtD
Docetaxel—Cardiac disorder—Capecitabine—esophageal cancer	5.67e-05	0.000981	CcSEcCtD
Docetaxel—Flushing—Capecitabine—esophageal cancer	5.67e-05	0.000981	CcSEcCtD
Docetaxel—Anorexia—Cisplatin—esophageal cancer	5.61e-05	0.000971	CcSEcCtD
Docetaxel—Angiopathy—Capecitabine—esophageal cancer	5.54e-05	0.000959	CcSEcCtD
Docetaxel—Immune system disorder—Capecitabine—esophageal cancer	5.52e-05	0.000955	CcSEcCtD
Docetaxel—Mediastinal disorder—Capecitabine—esophageal cancer	5.51e-05	0.000952	CcSEcCtD
Docetaxel—Hypotension—Cisplatin—esophageal cancer	5.5e-05	0.000952	CcSEcCtD
Docetaxel—Chills—Capecitabine—esophageal cancer	5.48e-05	0.000948	CcSEcCtD
Docetaxel—Arrhythmia—Capecitabine—esophageal cancer	5.46e-05	0.000944	CcSEcCtD
Docetaxel—Alopecia—Capecitabine—esophageal cancer	5.4e-05	0.000934	CcSEcCtD
Docetaxel—Pancytopenia—Methotrexate—esophageal cancer	5.4e-05	0.000933	CcSEcCtD
Docetaxel—Musculoskeletal discomfort—Cisplatin—esophageal cancer	5.37e-05	0.000928	CcSEcCtD
Docetaxel—Mental disorder—Capecitabine—esophageal cancer	5.35e-05	0.000926	CcSEcCtD
Docetaxel—ABCB1—lung—esophageal cancer	5.34e-05	0.00236	CbGeAlD
Docetaxel—Malnutrition—Capecitabine—esophageal cancer	5.32e-05	0.00092	CcSEcCtD
Docetaxel—Erythema—Capecitabine—esophageal cancer	5.32e-05	0.00092	CcSEcCtD
Docetaxel—Neutropenia—Methotrexate—esophageal cancer	5.31e-05	0.000919	CcSEcCtD
Docetaxel—Paraesthesia—Cisplatin—esophageal cancer	5.29e-05	0.000915	CcSEcCtD
Docetaxel—Dyspnoea—Cisplatin—esophageal cancer	5.25e-05	0.000908	CcSEcCtD
Docetaxel—Dysgeusia—Capecitabine—esophageal cancer	5.21e-05	0.000901	CcSEcCtD
Docetaxel—Back pain—Capecitabine—esophageal cancer	5.15e-05	0.00089	CcSEcCtD
Docetaxel—Decreased appetite—Cisplatin—esophageal cancer	5.12e-05	0.000885	CcSEcCtD
Docetaxel—Muscle spasms—Capecitabine—esophageal cancer	5.11e-05	0.000884	CcSEcCtD
Docetaxel—Pneumonia—Methotrexate—esophageal cancer	5.1e-05	0.000881	CcSEcCtD
Docetaxel—Gastrointestinal disorder—Cisplatin—esophageal cancer	5.08e-05	0.000879	CcSEcCtD
Docetaxel—Infestation NOS—Methotrexate—esophageal cancer	5.07e-05	0.000876	CcSEcCtD
Docetaxel—Infestation—Methotrexate—esophageal cancer	5.07e-05	0.000876	CcSEcCtD
Docetaxel—Pain—Cisplatin—esophageal cancer	5.04e-05	0.000871	CcSEcCtD
Docetaxel—Stevens-Johnson syndrome—Methotrexate—esophageal cancer	5.02e-05	0.000869	CcSEcCtD
Docetaxel—Renal failure—Methotrexate—esophageal cancer	4.98e-05	0.000861	CcSEcCtD
Docetaxel—Stomatitis—Methotrexate—esophageal cancer	4.94e-05	0.000854	CcSEcCtD
Docetaxel—Conjunctivitis—Methotrexate—esophageal cancer	4.93e-05	0.000852	CcSEcCtD
Docetaxel—Anaemia—Capecitabine—esophageal cancer	4.92e-05	0.00085	CcSEcCtD
Docetaxel—Feeling abnormal—Cisplatin—esophageal cancer	4.85e-05	0.000839	CcSEcCtD
Docetaxel—Hepatobiliary disease—Methotrexate—esophageal cancer	4.79e-05	0.000829	CcSEcCtD
Docetaxel—Epistaxis—Methotrexate—esophageal cancer	4.78e-05	0.000827	CcSEcCtD
Docetaxel—Syncope—Capecitabine—esophageal cancer	4.77e-05	0.000825	CcSEcCtD
Docetaxel—Leukopenia—Capecitabine—esophageal cancer	4.76e-05	0.000823	CcSEcCtD
Docetaxel—Agranulocytosis—Methotrexate—esophageal cancer	4.73e-05	0.000818	CcSEcCtD
Docetaxel—Palpitations—Capecitabine—esophageal cancer	4.7e-05	0.000813	CcSEcCtD
Docetaxel—Loss of consciousness—Capecitabine—esophageal cancer	4.68e-05	0.000809	CcSEcCtD
Docetaxel—Body temperature increased—Cisplatin—esophageal cancer	4.66e-05	0.000805	CcSEcCtD
Docetaxel—Cough—Capecitabine—esophageal cancer	4.64e-05	0.000803	CcSEcCtD
Docetaxel—Hypertension—Capecitabine—esophageal cancer	4.59e-05	0.000794	CcSEcCtD
Docetaxel—Haemoglobin—Methotrexate—esophageal cancer	4.57e-05	0.000791	CcSEcCtD
Docetaxel—Hepatitis—Methotrexate—esophageal cancer	4.55e-05	0.000787	CcSEcCtD
Docetaxel—Haemorrhage—Methotrexate—esophageal cancer	4.55e-05	0.000787	CcSEcCtD
Docetaxel—Arthralgia—Capecitabine—esophageal cancer	4.53e-05	0.000783	CcSEcCtD
Docetaxel—Chest pain—Capecitabine—esophageal cancer	4.53e-05	0.000783	CcSEcCtD
Docetaxel—Myalgia—Capecitabine—esophageal cancer	4.53e-05	0.000783	CcSEcCtD
Docetaxel—Pharyngitis—Methotrexate—esophageal cancer	4.52e-05	0.000781	CcSEcCtD
Docetaxel—Unspecified disorder of skin and subcutaneous tissue—Capecitabine—esophageal cancer	4.5e-05	0.000778	CcSEcCtD
Docetaxel—Urinary tract disorder—Methotrexate—esophageal cancer	4.49e-05	0.000777	CcSEcCtD
Docetaxel—Urethral disorder—Methotrexate—esophageal cancer	4.46e-05	0.000771	CcSEcCtD
Docetaxel—Dry mouth—Capecitabine—esophageal cancer	4.43e-05	0.000766	CcSEcCtD
Docetaxel—Visual impairment—Methotrexate—esophageal cancer	4.38e-05	0.000758	CcSEcCtD
Docetaxel—Confusional state—Capecitabine—esophageal cancer	4.38e-05	0.000757	CcSEcCtD
Docetaxel—Oedema—Capecitabine—esophageal cancer	4.34e-05	0.000751	CcSEcCtD
Docetaxel—Hypersensitivity—Cisplatin—esophageal cancer	4.34e-05	0.00075	CcSEcCtD
Docetaxel—Infection—Capecitabine—esophageal cancer	4.31e-05	0.000746	CcSEcCtD
Docetaxel—Erythema multiforme—Methotrexate—esophageal cancer	4.3e-05	0.000744	CcSEcCtD
Docetaxel—Shock—Capecitabine—esophageal cancer	4.27e-05	0.000739	CcSEcCtD
Docetaxel—Nervous system disorder—Capecitabine—esophageal cancer	4.26e-05	0.000736	CcSEcCtD
Docetaxel—Eye disorder—Methotrexate—esophageal cancer	4.25e-05	0.000735	CcSEcCtD
Docetaxel—Thrombocytopenia—Capecitabine—esophageal cancer	4.25e-05	0.000735	CcSEcCtD
Docetaxel—Tachycardia—Capecitabine—esophageal cancer	4.24e-05	0.000733	CcSEcCtD
Docetaxel—Asthenia—Cisplatin—esophageal cancer	4.23e-05	0.000731	CcSEcCtD
Docetaxel—Cardiac disorder—Methotrexate—esophageal cancer	4.22e-05	0.00073	CcSEcCtD
Docetaxel—Skin disorder—Capecitabine—esophageal cancer	4.22e-05	0.000729	CcSEcCtD
Docetaxel—Anorexia—Capecitabine—esophageal cancer	4.14e-05	0.000716	CcSEcCtD
Docetaxel—Angiopathy—Methotrexate—esophageal cancer	4.13e-05	0.000714	CcSEcCtD
Docetaxel—Immune system disorder—Methotrexate—esophageal cancer	4.11e-05	0.000711	CcSEcCtD
Docetaxel—Mediastinal disorder—Methotrexate—esophageal cancer	4.1e-05	0.000709	CcSEcCtD
Docetaxel—Chills—Methotrexate—esophageal cancer	4.08e-05	0.000706	CcSEcCtD
Docetaxel—Hypotension—Capecitabine—esophageal cancer	4.06e-05	0.000702	CcSEcCtD
Docetaxel—Diarrhoea—Cisplatin—esophageal cancer	4.03e-05	0.000697	CcSEcCtD
Docetaxel—Alopecia—Methotrexate—esophageal cancer	4.02e-05	0.000695	CcSEcCtD
Docetaxel—Mental disorder—Methotrexate—esophageal cancer	3.99e-05	0.000689	CcSEcCtD
Docetaxel—Erythema—Methotrexate—esophageal cancer	3.96e-05	0.000685	CcSEcCtD
Docetaxel—Malnutrition—Methotrexate—esophageal cancer	3.96e-05	0.000685	CcSEcCtD
Docetaxel—Musculoskeletal discomfort—Capecitabine—esophageal cancer	3.96e-05	0.000684	CcSEcCtD
Docetaxel—Insomnia—Capecitabine—esophageal cancer	3.93e-05	0.000679	CcSEcCtD
Docetaxel—Paraesthesia—Capecitabine—esophageal cancer	3.9e-05	0.000674	CcSEcCtD
Docetaxel—Dysgeusia—Methotrexate—esophageal cancer	3.88e-05	0.000671	CcSEcCtD
Docetaxel—Dyspnoea—Capecitabine—esophageal cancer	3.87e-05	0.000669	CcSEcCtD
Docetaxel—Back pain—Methotrexate—esophageal cancer	3.83e-05	0.000662	CcSEcCtD
Docetaxel—Dyspepsia—Capecitabine—esophageal cancer	3.82e-05	0.000661	CcSEcCtD
Docetaxel—Decreased appetite—Capecitabine—esophageal cancer	3.77e-05	0.000653	CcSEcCtD
Docetaxel—Gastrointestinal disorder—Capecitabine—esophageal cancer	3.75e-05	0.000648	CcSEcCtD
Docetaxel—Vomiting—Cisplatin—esophageal cancer	3.74e-05	0.000648	CcSEcCtD
Docetaxel—Fatigue—Capecitabine—esophageal cancer	3.74e-05	0.000647	CcSEcCtD
Docetaxel—Rash—Cisplatin—esophageal cancer	3.71e-05	0.000642	CcSEcCtD
Docetaxel—Constipation—Capecitabine—esophageal cancer	3.71e-05	0.000642	CcSEcCtD
Docetaxel—Pain—Capecitabine—esophageal cancer	3.71e-05	0.000642	CcSEcCtD
Docetaxel—Dermatitis—Cisplatin—esophageal cancer	3.71e-05	0.000642	CcSEcCtD
Docetaxel—Anaemia—Methotrexate—esophageal cancer	3.66e-05	0.000633	CcSEcCtD
Docetaxel—ABCB1—lymph node—esophageal cancer	3.65e-05	0.00162	CbGeAlD
Docetaxel—Feeling abnormal—Capecitabine—esophageal cancer	3.58e-05	0.000619	CcSEcCtD
Docetaxel—Gastrointestinal pain—Capecitabine—esophageal cancer	3.55e-05	0.000614	CcSEcCtD
Docetaxel—Leukopenia—Methotrexate—esophageal cancer	3.54e-05	0.000613	CcSEcCtD
Docetaxel—Nausea—Cisplatin—esophageal cancer	3.5e-05	0.000605	CcSEcCtD
Docetaxel—Cough—Methotrexate—esophageal cancer	3.46e-05	0.000598	CcSEcCtD
Docetaxel—Abdominal pain—Capecitabine—esophageal cancer	3.43e-05	0.000594	CcSEcCtD
Docetaxel—Body temperature increased—Capecitabine—esophageal cancer	3.43e-05	0.000594	CcSEcCtD
Docetaxel—Convulsion—Methotrexate—esophageal cancer	3.43e-05	0.000593	CcSEcCtD
Docetaxel—Myalgia—Methotrexate—esophageal cancer	3.37e-05	0.000583	CcSEcCtD
Docetaxel—Arthralgia—Methotrexate—esophageal cancer	3.37e-05	0.000583	CcSEcCtD
Docetaxel—Chest pain—Methotrexate—esophageal cancer	3.37e-05	0.000583	CcSEcCtD
Docetaxel—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—esophageal cancer	3.35e-05	0.000579	CcSEcCtD
Docetaxel—Confusional state—Methotrexate—esophageal cancer	3.26e-05	0.000564	CcSEcCtD
Docetaxel—Anaphylactic shock—Methotrexate—esophageal cancer	3.23e-05	0.000559	CcSEcCtD
Docetaxel—Infection—Methotrexate—esophageal cancer	3.21e-05	0.000555	CcSEcCtD
Docetaxel—Hypersensitivity—Capecitabine—esophageal cancer	3.2e-05	0.000553	CcSEcCtD
Docetaxel—Nervous system disorder—Methotrexate—esophageal cancer	3.17e-05	0.000548	CcSEcCtD
Docetaxel—Thrombocytopenia—Methotrexate—esophageal cancer	3.16e-05	0.000547	CcSEcCtD
Docetaxel—Skin disorder—Methotrexate—esophageal cancer	3.14e-05	0.000543	CcSEcCtD
Docetaxel—Asthenia—Capecitabine—esophageal cancer	3.12e-05	0.000539	CcSEcCtD
Docetaxel—Anorexia—Methotrexate—esophageal cancer	3.08e-05	0.000533	CcSEcCtD
Docetaxel—Pruritus—Capecitabine—esophageal cancer	3.07e-05	0.000531	CcSEcCtD
Docetaxel—Hypotension—Methotrexate—esophageal cancer	3.02e-05	0.000522	CcSEcCtD
Docetaxel—Diarrhoea—Capecitabine—esophageal cancer	2.97e-05	0.000514	CcSEcCtD
Docetaxel—Musculoskeletal discomfort—Methotrexate—esophageal cancer	2.94e-05	0.000509	CcSEcCtD
Docetaxel—Insomnia—Methotrexate—esophageal cancer	2.92e-05	0.000506	CcSEcCtD
Docetaxel—Paraesthesia—Methotrexate—esophageal cancer	2.9e-05	0.000502	CcSEcCtD
Docetaxel—Dyspnoea—Methotrexate—esophageal cancer	2.88e-05	0.000498	CcSEcCtD
Docetaxel—Somnolence—Methotrexate—esophageal cancer	2.87e-05	0.000497	CcSEcCtD
Docetaxel—Dizziness—Capecitabine—esophageal cancer	2.87e-05	0.000496	CcSEcCtD
Docetaxel—Dyspepsia—Methotrexate—esophageal cancer	2.85e-05	0.000492	CcSEcCtD
Docetaxel—Decreased appetite—Methotrexate—esophageal cancer	2.81e-05	0.000486	CcSEcCtD
Docetaxel—Gastrointestinal disorder—Methotrexate—esophageal cancer	2.79e-05	0.000483	CcSEcCtD
Docetaxel—Fatigue—Methotrexate—esophageal cancer	2.79e-05	0.000482	CcSEcCtD
Docetaxel—Pain—Methotrexate—esophageal cancer	2.76e-05	0.000478	CcSEcCtD
Docetaxel—Vomiting—Capecitabine—esophageal cancer	2.76e-05	0.000477	CcSEcCtD
Docetaxel—Rash—Capecitabine—esophageal cancer	2.74e-05	0.000473	CcSEcCtD
Docetaxel—Dermatitis—Capecitabine—esophageal cancer	2.73e-05	0.000473	CcSEcCtD
Docetaxel—Headache—Capecitabine—esophageal cancer	2.72e-05	0.00047	CcSEcCtD
Docetaxel—Feeling abnormal—Methotrexate—esophageal cancer	2.66e-05	0.000461	CcSEcCtD
Docetaxel—Gastrointestinal pain—Methotrexate—esophageal cancer	2.64e-05	0.000457	CcSEcCtD
Docetaxel—Nausea—Capecitabine—esophageal cancer	2.58e-05	0.000446	CcSEcCtD
Docetaxel—Abdominal pain—Methotrexate—esophageal cancer	2.55e-05	0.000442	CcSEcCtD
Docetaxel—Body temperature increased—Methotrexate—esophageal cancer	2.55e-05	0.000442	CcSEcCtD
Docetaxel—Hypersensitivity—Methotrexate—esophageal cancer	2.38e-05	0.000412	CcSEcCtD
Docetaxel—Asthenia—Methotrexate—esophageal cancer	2.32e-05	0.000401	CcSEcCtD
Docetaxel—Pruritus—Methotrexate—esophageal cancer	2.29e-05	0.000395	CcSEcCtD
Docetaxel—Diarrhoea—Methotrexate—esophageal cancer	2.21e-05	0.000382	CcSEcCtD
Docetaxel—Dizziness—Methotrexate—esophageal cancer	2.14e-05	0.00037	CcSEcCtD
Docetaxel—Vomiting—Methotrexate—esophageal cancer	2.05e-05	0.000355	CcSEcCtD
Docetaxel—Rash—Methotrexate—esophageal cancer	2.04e-05	0.000352	CcSEcCtD
Docetaxel—Dermatitis—Methotrexate—esophageal cancer	2.04e-05	0.000352	CcSEcCtD
Docetaxel—Headache—Methotrexate—esophageal cancer	2.02e-05	0.00035	CcSEcCtD
Docetaxel—Nausea—Methotrexate—esophageal cancer	1.92e-05	0.000332	CcSEcCtD
Docetaxel—ABCC1—Metabolism—PSME1—esophageal cancer	3.24e-06	5.43e-05	CbGpPWpGaD
Docetaxel—EGFR—Innate Immune System—CASP8—esophageal cancer	3.23e-06	5.42e-05	CbGpPWpGaD
Docetaxel—ABCB1—Integrated Pancreatic Cancer Pathway—PTGS2—esophageal cancer	3.22e-06	5.4e-05	CbGpPWpGaD
Docetaxel—EGFR—Innate Immune System—CREBBP—esophageal cancer	3.22e-06	5.4e-05	CbGpPWpGaD
Docetaxel—CYP3A7—Metabolism—ALDH2—esophageal cancer	3.21e-06	5.39e-05	CbGpPWpGaD
Docetaxel—BCL2—Immune System—CASP8—esophageal cancer	3.18e-06	5.34e-05	CbGpPWpGaD
Docetaxel—CYP1B1—Metabolism—PTGS1—esophageal cancer	3.18e-06	5.33e-05	CbGpPWpGaD
Docetaxel—CYP1B1—Metabolism—ENO1—esophageal cancer	3.18e-06	5.33e-05	CbGpPWpGaD
Docetaxel—BCL2—Immune System—CREBBP—esophageal cancer	3.17e-06	5.32e-05	CbGpPWpGaD
Docetaxel—BCL2—Innate Immune System—EGFR—esophageal cancer	3.16e-06	5.3e-05	CbGpPWpGaD
Docetaxel—CYP3A5—Metabolism—TYMP—esophageal cancer	3.15e-06	5.29e-05	CbGpPWpGaD
Docetaxel—CYP1B1—Metabolism—PSME2—esophageal cancer	3.13e-06	5.25e-05	CbGpPWpGaD
Docetaxel—CYP1B1—Metabolism—PSME1—esophageal cancer	3.13e-06	5.25e-05	CbGpPWpGaD
Docetaxel—EGFR—Signaling Pathways—GNG7—esophageal cancer	3.1e-06	5.2e-05	CbGpPWpGaD
Docetaxel—ABCG2—Metabolism—GSTT1—esophageal cancer	3.09e-06	5.17e-05	CbGpPWpGaD
Docetaxel—CYP3A5—Metabolism—CYP26A1—esophageal cancer	3.07e-06	5.14e-05	CbGpPWpGaD
Docetaxel—CYP3A7—Metabolism—GSTT1—esophageal cancer	3.06e-06	5.13e-05	CbGpPWpGaD
Docetaxel—ABCB1—Metabolism—CA2—esophageal cancer	3.05e-06	5.12e-05	CbGpPWpGaD
Docetaxel—EGFR—Developmental Biology—ERBB2—esophageal cancer	3.05e-06	5.12e-05	CbGpPWpGaD
Docetaxel—ABCG2—Metabolism—CYP2A6—esophageal cancer	3.05e-06	5.11e-05	CbGpPWpGaD
Docetaxel—CYP3A7—Metabolism—CYP2A6—esophageal cancer	3.02e-06	5.07e-05	CbGpPWpGaD
Docetaxel—CYP3A5—Metabolism—ALOX15—esophageal cancer	2.99e-06	5.01e-05	CbGpPWpGaD
Docetaxel—TUBB4A—Cell Cycle—TP53—esophageal cancer	2.99e-06	5.01e-05	CbGpPWpGaD
Docetaxel—NR1I2—Gene Expression—MYC—esophageal cancer	2.97e-06	4.99e-05	CbGpPWpGaD
Docetaxel—ABCB1—Integrated Pancreatic Cancer Pathway—CCND1—esophageal cancer	2.91e-06	4.88e-05	CbGpPWpGaD
Docetaxel—EGFR—Signaling Pathways—XIAP—esophageal cancer	2.91e-06	4.87e-05	CbGpPWpGaD
Docetaxel—ABCC1—Disease—TGFBR2—esophageal cancer	2.9e-06	4.87e-05	CbGpPWpGaD
Docetaxel—EGFR—Immune System—ABL1—esophageal cancer	2.9e-06	4.86e-05	CbGpPWpGaD
Docetaxel—ABCG2—Metabolism—PTGS1—esophageal cancer	2.89e-06	4.85e-05	CbGpPWpGaD
Docetaxel—ABCG2—Metabolism—ENO1—esophageal cancer	2.89e-06	4.85e-05	CbGpPWpGaD
Docetaxel—ABCG2—Transmembrane transport of small molecules—CREBBP—esophageal cancer	2.89e-06	4.84e-05	CbGpPWpGaD
Docetaxel—CYP3A7—Metabolism—ENO1—esophageal cancer	2.87e-06	4.81e-05	CbGpPWpGaD
Docetaxel—CYP3A7—Metabolism—PTGS1—esophageal cancer	2.87e-06	4.81e-05	CbGpPWpGaD
Docetaxel—CYP3A5—Metabolism—TPI1—esophageal cancer	2.85e-06	4.78e-05	CbGpPWpGaD
Docetaxel—CYP3A5—Metabolism—GSTO1—esophageal cancer	2.85e-06	4.78e-05	CbGpPWpGaD
Docetaxel—ABCG2—Metabolism—PSME2—esophageal cancer	2.85e-06	4.78e-05	CbGpPWpGaD
Docetaxel—ABCG2—Metabolism—PSME1—esophageal cancer	2.85e-06	4.78e-05	CbGpPWpGaD
Docetaxel—EGFR—Signaling by NGF—PIK3CA—esophageal cancer	2.84e-06	4.77e-05	CbGpPWpGaD
Docetaxel—ABCB1—Metabolism—PLCE1—esophageal cancer	2.84e-06	4.76e-05	CbGpPWpGaD
Docetaxel—ABCB1—Metabolism—ADH7—esophageal cancer	2.84e-06	4.76e-05	CbGpPWpGaD
Docetaxel—ABCC1—Metabolism of lipids and lipoproteins—PTGS2—esophageal cancer	2.83e-06	4.74e-05	CbGpPWpGaD
Docetaxel—CYP3A7—Metabolism—PSME1—esophageal cancer	2.82e-06	4.74e-05	CbGpPWpGaD
Docetaxel—CYP3A7—Metabolism—PSME2—esophageal cancer	2.82e-06	4.74e-05	CbGpPWpGaD
Docetaxel—ABCB1—Integrated Pancreatic Cancer Pathway—CDKN1A—esophageal cancer	2.82e-06	4.72e-05	CbGpPWpGaD
Docetaxel—ABCC1—Metabolism—CYP1B1—esophageal cancer	2.79e-06	4.69e-05	CbGpPWpGaD
Docetaxel—EGFR—Innate Immune System—BCL2—esophageal cancer	2.77e-06	4.65e-05	CbGpPWpGaD
Docetaxel—EGFR—Signaling Pathways—CTNNA1—esophageal cancer	2.75e-06	4.61e-05	CbGpPWpGaD
Docetaxel—ABCC1—Disease—SMAD4—esophageal cancer	2.75e-06	4.61e-05	CbGpPWpGaD
Docetaxel—BCL2—Innate Immune System—PIK3CA—esophageal cancer	2.74e-06	4.6e-05	CbGpPWpGaD
Docetaxel—EGFR—Disease—TGFBR2—esophageal cancer	2.74e-06	4.59e-05	CbGpPWpGaD
Docetaxel—CYP1B1—Metabolism of lipids and lipoproteins—PTGS2—esophageal cancer	2.73e-06	4.59e-05	CbGpPWpGaD
Docetaxel—CYP3A5—Metabolism—ALDOB—esophageal cancer	2.73e-06	4.58e-05	CbGpPWpGaD
Docetaxel—EGFR—Signaling Pathways—CXCL2—esophageal cancer	2.73e-06	4.58e-05	CbGpPWpGaD
Docetaxel—TUBB4B—Cell Cycle—TP53—esophageal cancer	2.73e-06	4.58e-05	CbGpPWpGaD
Docetaxel—EGFR—Innate Immune System—ERBB2—esophageal cancer	2.69e-06	4.52e-05	CbGpPWpGaD
Docetaxel—ABCB1—Integrated Pancreatic Cancer Pathway—EP300—esophageal cancer	2.68e-06	4.49e-05	CbGpPWpGaD
Docetaxel—BCL2—Immune System—ERBB2—esophageal cancer	2.65e-06	4.45e-05	CbGpPWpGaD
Docetaxel—CYP3A5—Metabolism—GAPDH—esophageal cancer	2.63e-06	4.41e-05	CbGpPWpGaD
Docetaxel—ABCC1—Metabolism—CYP19A1—esophageal cancer	2.63e-06	4.41e-05	CbGpPWpGaD
Docetaxel—CYP3A5—Metabolism—CRABP1—esophageal cancer	2.61e-06	4.37e-05	CbGpPWpGaD
Docetaxel—EGFR—Disease—SMAD4—esophageal cancer	2.59e-06	4.34e-05	CbGpPWpGaD
Docetaxel—EGFR—Adaptive Immune System—ERBB2—esophageal cancer	2.59e-06	4.34e-05	CbGpPWpGaD
Docetaxel—EGFR—Signaling Pathways—PSME1—esophageal cancer	2.55e-06	4.28e-05	CbGpPWpGaD
Docetaxel—EGFR—Signaling Pathways—PSME2—esophageal cancer	2.55e-06	4.28e-05	CbGpPWpGaD
Docetaxel—CYP1B1—Metabolism—CYP19A1—esophageal cancer	2.54e-06	4.26e-05	CbGpPWpGaD
Docetaxel—EGFR—Signaling Pathways—ANXA1—esophageal cancer	2.54e-06	4.26e-05	CbGpPWpGaD
Docetaxel—ABCB1—Metabolism—ADH1B—esophageal cancer	2.49e-06	4.17e-05	CbGpPWpGaD
Docetaxel—EGFR—Developmental Biology—EP300—esophageal cancer	2.48e-06	4.16e-05	CbGpPWpGaD
Docetaxel—CYP3A5—Metabolism—GNG7—esophageal cancer	2.48e-06	4.16e-05	CbGpPWpGaD
Docetaxel—EGFR—Signaling Pathways—SST—esophageal cancer	2.47e-06	4.14e-05	CbGpPWpGaD
Docetaxel—SLCO1B3—Metabolism of lipids and lipoproteins—PIK3CA—esophageal cancer	2.46e-06	4.13e-05	CbGpPWpGaD
Docetaxel—ABCG2—Metabolism—CYP1B1—esophageal cancer	2.46e-06	4.12e-05	CbGpPWpGaD
Docetaxel—CYP3A7—Metabolism—CYP1B1—esophageal cancer	2.44e-06	4.09e-05	CbGpPWpGaD
Docetaxel—ABCB1—Transmembrane transport of small molecules—HMOX1—esophageal cancer	2.43e-06	4.08e-05	CbGpPWpGaD
Docetaxel—CYP3A4—Metabolism—BLVRB—esophageal cancer	2.42e-06	4.06e-05	CbGpPWpGaD
Docetaxel—CYP3A4—Metabolism—SLC52A3—esophageal cancer	2.42e-06	4.06e-05	CbGpPWpGaD
Docetaxel—EGFR—Signaling Pathways—NOTCH3—esophageal cancer	2.41e-06	4.04e-05	CbGpPWpGaD
Docetaxel—EGFR—Signaling Pathways—GHRL—esophageal cancer	2.41e-06	4.04e-05	CbGpPWpGaD
Docetaxel—ABCC1—Metabolism—HMOX1—esophageal cancer	2.4e-06	4.02e-05	CbGpPWpGaD
Docetaxel—ABCB1—Metabolism—TYMP—esophageal cancer	2.38e-06	3.99e-05	CbGpPWpGaD
Docetaxel—EGFR—Signaling Pathways—FBXW7—esophageal cancer	2.37e-06	3.97e-05	CbGpPWpGaD
Docetaxel—ABCC1—Metabolism of lipids and lipoproteins—EP300—esophageal cancer	2.35e-06	3.94e-05	CbGpPWpGaD
Docetaxel—ABCB1—Integrated Pancreatic Cancer Pathway—MYC—esophageal cancer	2.33e-06	3.92e-05	CbGpPWpGaD
Docetaxel—CYP3A5—Metabolism—ALDH2—esophageal cancer	2.32e-06	3.9e-05	CbGpPWpGaD
Docetaxel—CYP1B1—Metabolism—HMOX1—esophageal cancer	2.32e-06	3.89e-05	CbGpPWpGaD
Docetaxel—ABCB1—Metabolism—CYP26A1—esophageal cancer	2.31e-06	3.88e-05	CbGpPWpGaD
Docetaxel—ABCG2—Metabolism—CYP19A1—esophageal cancer	2.31e-06	3.88e-05	CbGpPWpGaD
Docetaxel—EGFR—Innate Immune System—CDKN1A—esophageal cancer	2.3e-06	3.86e-05	CbGpPWpGaD
Docetaxel—ABCC1—Metabolism—ABCB1—esophageal cancer	2.3e-06	3.86e-05	CbGpPWpGaD
Docetaxel—CYP3A7—Metabolism—CYP19A1—esophageal cancer	2.29e-06	3.84e-05	CbGpPWpGaD
Docetaxel—ABCB1—Integrated Pancreatic Cancer Pathway—EGFR—esophageal cancer	2.28e-06	3.83e-05	CbGpPWpGaD
Docetaxel—CYP1B1—Metabolism of lipids and lipoproteins—EP300—esophageal cancer	2.27e-06	3.81e-05	CbGpPWpGaD
Docetaxel—BCL2—Immune System—CDKN1A—esophageal cancer	2.27e-06	3.81e-05	CbGpPWpGaD
Docetaxel—ABCB1—Metabolism—ALOX15—esophageal cancer	2.25e-06	3.78e-05	CbGpPWpGaD
Docetaxel—ABCC1—Disease—HIF1A—esophageal cancer	2.25e-06	3.77e-05	CbGpPWpGaD
Docetaxel—CYP1B1—Metabolism—ABCB1—esophageal cancer	2.22e-06	3.73e-05	CbGpPWpGaD
Docetaxel—EGFR—Adaptive Immune System—CDKN1A—esophageal cancer	2.21e-06	3.71e-05	CbGpPWpGaD
Docetaxel—CYP3A5—Metabolism—GSTT1—esophageal cancer	2.21e-06	3.71e-05	CbGpPWpGaD
Docetaxel—EGFR—Immune System—TLR4—esophageal cancer	2.19e-06	3.68e-05	CbGpPWpGaD
Docetaxel—EGFR—Innate Immune System—EP300—esophageal cancer	2.19e-06	3.68e-05	CbGpPWpGaD
Docetaxel—CYP3A5—Metabolism—CYP2A6—esophageal cancer	2.18e-06	3.66e-05	CbGpPWpGaD
Docetaxel—SLCO1B3—Metabolism—CREBBP—esophageal cancer	2.17e-06	3.65e-05	CbGpPWpGaD
Docetaxel—EGFR—Signaling Pathways—NOTCH2—esophageal cancer	2.16e-06	3.62e-05	CbGpPWpGaD
Docetaxel—BCL2—Immune System—EP300—esophageal cancer	2.16e-06	3.62e-05	CbGpPWpGaD
Docetaxel—ABCB1—Metabolism—TPI1—esophageal cancer	2.15e-06	3.61e-05	CbGpPWpGaD
Docetaxel—ABCB1—Metabolism—GSTO1—esophageal cancer	2.15e-06	3.61e-05	CbGpPWpGaD
Docetaxel—EGFR—Disease—HIF1A—esophageal cancer	2.12e-06	3.55e-05	CbGpPWpGaD
Docetaxel—ABCG2—Metabolism—HMOX1—esophageal cancer	2.11e-06	3.54e-05	CbGpPWpGaD
Docetaxel—CYP3A7—Metabolism—HMOX1—esophageal cancer	2.09e-06	3.51e-05	CbGpPWpGaD
Docetaxel—CYP3A5—Metabolism—PTGS1—esophageal cancer	2.07e-06	3.47e-05	CbGpPWpGaD
Docetaxel—CYP3A5—Metabolism—ENO1—esophageal cancer	2.07e-06	3.47e-05	CbGpPWpGaD
Docetaxel—ABCB1—Metabolism—ALDOB—esophageal cancer	2.06e-06	3.46e-05	CbGpPWpGaD
Docetaxel—CYP3A4—Metabolism—SLC10A2—esophageal cancer	2.06e-06	3.45e-05	CbGpPWpGaD
Docetaxel—CYP3A4—Metabolism—CA1—esophageal cancer	2.06e-06	3.45e-05	CbGpPWpGaD
Docetaxel—ABCC1—Disease—NOS2—esophageal cancer	2.04e-06	3.43e-05	CbGpPWpGaD
Docetaxel—CYP3A5—Metabolism—PSME2—esophageal cancer	2.04e-06	3.42e-05	CbGpPWpGaD
Docetaxel—CYP3A5—Metabolism—PSME1—esophageal cancer	2.04e-06	3.42e-05	CbGpPWpGaD
Docetaxel—ABCC1—Disease—NOTCH1—esophageal cancer	2.02e-06	3.4e-05	CbGpPWpGaD
Docetaxel—ABCG2—Metabolism—ABCB1—esophageal cancer	2.02e-06	3.4e-05	CbGpPWpGaD
Docetaxel—CYP3A7—Metabolism—ABCB1—esophageal cancer	2.01e-06	3.37e-05	CbGpPWpGaD
Docetaxel—ABCB1—Metabolism—GAPDH—esophageal cancer	1.99e-06	3.33e-05	CbGpPWpGaD
Docetaxel—ABCB1—Integrated Pancreatic Cancer Pathway—PIK3CA—esophageal cancer	1.98e-06	3.32e-05	CbGpPWpGaD
Docetaxel—ABCB1—Metabolism—CRABP1—esophageal cancer	1.97e-06	3.3e-05	CbGpPWpGaD
Docetaxel—SLCO1B3—Metabolism—NOS3—esophageal cancer	1.95e-06	3.27e-05	CbGpPWpGaD
Docetaxel—EGFR—Disease—NOS2—esophageal cancer	1.93e-06	3.23e-05	CbGpPWpGaD
Docetaxel—ABCB1—Integrated Pancreatic Cancer Pathway—TP53—esophageal cancer	1.92e-06	3.22e-05	CbGpPWpGaD
Docetaxel—EGFR—Signaling Pathways—TGFBR2—esophageal cancer	1.92e-06	3.21e-05	CbGpPWpGaD
Docetaxel—EGFR—Disease—NOTCH1—esophageal cancer	1.91e-06	3.2e-05	CbGpPWpGaD
Docetaxel—EGFR—Immune System—CASP8—esophageal cancer	1.88e-06	3.16e-05	CbGpPWpGaD
Docetaxel—CYP3A4—Metabolism—CA2—esophageal cancer	1.88e-06	3.16e-05	CbGpPWpGaD
Docetaxel—EGFR—Immune System—CREBBP—esophageal cancer	1.87e-06	3.14e-05	CbGpPWpGaD
Docetaxel—ABCB1—Metabolism—GNG7—esophageal cancer	1.87e-06	3.14e-05	CbGpPWpGaD
Docetaxel—BCL2—Immune System—EGFR—esophageal cancer	1.84e-06	3.09e-05	CbGpPWpGaD
Docetaxel—ABCC1—Disease—CREBBP—esophageal cancer	1.84e-06	3.08e-05	CbGpPWpGaD
Docetaxel—EGFR—Signaling Pathways—SMAD4—esophageal cancer	1.81e-06	3.04e-05	CbGpPWpGaD
Docetaxel—SLCO1B3—Metabolism—PTGS2—esophageal cancer	1.78e-06	2.99e-05	CbGpPWpGaD
Docetaxel—CYP3A5—Metabolism—CYP1B1—esophageal cancer	1.76e-06	2.95e-05	CbGpPWpGaD
Docetaxel—ABCB1—Metabolism—ALDH2—esophageal cancer	1.75e-06	2.94e-05	CbGpPWpGaD
Docetaxel—CYP3A4—Metabolism—PLCE1—esophageal cancer	1.75e-06	2.93e-05	CbGpPWpGaD
Docetaxel—CYP3A4—Metabolism—ADH7—esophageal cancer	1.75e-06	2.93e-05	CbGpPWpGaD
Docetaxel—ABCC1—Metabolism of lipids and lipoproteins—PIK3CA—esophageal cancer	1.74e-06	2.92e-05	CbGpPWpGaD
Docetaxel—EGFR—Disease—CREBBP—esophageal cancer	1.73e-06	2.9e-05	CbGpPWpGaD
Docetaxel—CYP1B1—Metabolism of lipids and lipoproteins—PIK3CA—esophageal cancer	1.68e-06	2.82e-05	CbGpPWpGaD
Docetaxel—ABCB1—Metabolism—GSTT1—esophageal cancer	1.67e-06	2.8e-05	CbGpPWpGaD
Docetaxel—CYP3A5—Metabolism—CYP19A1—esophageal cancer	1.66e-06	2.78e-05	CbGpPWpGaD
Docetaxel—ABCB1—Metabolism—CYP2A6—esophageal cancer	1.65e-06	2.77e-05	CbGpPWpGaD
Docetaxel—ABCC1—Disease—NOS3—esophageal cancer	1.64e-06	2.76e-05	CbGpPWpGaD
Docetaxel—EGFR—Innate Immune System—PIK3CA—esophageal cancer	1.62e-06	2.72e-05	CbGpPWpGaD
Docetaxel—EGFR—Immune System—BCL2—esophageal cancer	1.62e-06	2.71e-05	CbGpPWpGaD
Docetaxel—BCL2—Immune System—PIK3CA—esophageal cancer	1.6e-06	2.68e-05	CbGpPWpGaD
Docetaxel—EGFR—Immune System—ERBB2—esophageal cancer	1.57e-06	2.63e-05	CbGpPWpGaD
Docetaxel—ABCB1—Metabolism—ENO1—esophageal cancer	1.56e-06	2.62e-05	CbGpPWpGaD
Docetaxel—ABCB1—Metabolism—PTGS1—esophageal cancer	1.56e-06	2.62e-05	CbGpPWpGaD
Docetaxel—ABCB1—Transmembrane transport of small molecules—CREBBP—esophageal cancer	1.56e-06	2.62e-05	CbGpPWpGaD
Docetaxel—EGFR—Adaptive Immune System—PIK3CA—esophageal cancer	1.56e-06	2.61e-05	CbGpPWpGaD
Docetaxel—EGFR—Disease—NOS3—esophageal cancer	1.55e-06	2.6e-05	CbGpPWpGaD
Docetaxel—ABCB1—Metabolism—PSME1—esophageal cancer	1.54e-06	2.58e-05	CbGpPWpGaD
Docetaxel—ABCB1—Metabolism—PSME2—esophageal cancer	1.54e-06	2.58e-05	CbGpPWpGaD
Docetaxel—ABCC1—Metabolism—CREBBP—esophageal cancer	1.54e-06	2.58e-05	CbGpPWpGaD
Docetaxel—ABCC1—Disease—ERBB2—esophageal cancer	1.54e-06	2.58e-05	CbGpPWpGaD
Docetaxel—CYP3A4—Metabolism—ADH1B—esophageal cancer	1.53e-06	2.57e-05	CbGpPWpGaD
Docetaxel—CYP3A5—Metabolism—HMOX1—esophageal cancer	1.51e-06	2.53e-05	CbGpPWpGaD
Docetaxel—ABCC1—Disease—PTGS2—esophageal cancer	1.5e-06	2.52e-05	CbGpPWpGaD
Docetaxel—CYP1B1—Metabolism—CREBBP—esophageal cancer	1.49e-06	2.49e-05	CbGpPWpGaD
Docetaxel—EGFR—Signaling Pathways—HIF1A—esophageal cancer	1.48e-06	2.49e-05	CbGpPWpGaD
Docetaxel—SLCO1B3—Metabolism—EP300—esophageal cancer	1.48e-06	2.48e-05	CbGpPWpGaD
Docetaxel—CYP3A4—Metabolism—TYMP—esophageal cancer	1.47e-06	2.46e-05	CbGpPWpGaD
Docetaxel—CYP3A5—Metabolism—ABCB1—esophageal cancer	1.45e-06	2.43e-05	CbGpPWpGaD
Docetaxel—EGFR—Disease—ERBB2—esophageal cancer	1.45e-06	2.43e-05	CbGpPWpGaD
Docetaxel—CYP3A4—Metabolism—CYP26A1—esophageal cancer	1.43e-06	2.39e-05	CbGpPWpGaD
Docetaxel—EGFR—Signaling Pathways—KDR—esophageal cancer	1.42e-06	2.38e-05	CbGpPWpGaD
Docetaxel—EGFR—Disease—PTGS2—esophageal cancer	1.42e-06	2.38e-05	CbGpPWpGaD
Docetaxel—CYP3A4—Metabolism—ALOX15—esophageal cancer	1.39e-06	2.33e-05	CbGpPWpGaD
Docetaxel—ABCC1—Metabolism—NOS3—esophageal cancer	1.38e-06	2.31e-05	CbGpPWpGaD
Docetaxel—ABCG2—Metabolism—CREBBP—esophageal cancer	1.35e-06	2.27e-05	CbGpPWpGaD
Docetaxel—EGFR—Immune System—CDKN1A—esophageal cancer	1.34e-06	2.25e-05	CbGpPWpGaD
Docetaxel—CYP3A7—Metabolism—CREBBP—esophageal cancer	1.34e-06	2.25e-05	CbGpPWpGaD
Docetaxel—EGFR—Signaling Pathways—NOTCH1—esophageal cancer	1.34e-06	2.24e-05	CbGpPWpGaD
Docetaxel—CYP1B1—Metabolism—NOS3—esophageal cancer	1.33e-06	2.23e-05	CbGpPWpGaD
Docetaxel—ABCB1—Metabolism—CYP1B1—esophageal cancer	1.33e-06	2.23e-05	CbGpPWpGaD
Docetaxel—CYP3A4—Metabolism—GSTO1—esophageal cancer	1.33e-06	2.22e-05	CbGpPWpGaD
Docetaxel—CYP3A4—Metabolism—TPI1—esophageal cancer	1.33e-06	2.22e-05	CbGpPWpGaD
Docetaxel—ABCC1—Disease—CDKN1A—esophageal cancer	1.31e-06	2.2e-05	CbGpPWpGaD
Docetaxel—EGFR—Immune System—EP300—esophageal cancer	1.28e-06	2.14e-05	CbGpPWpGaD
Docetaxel—CYP3A4—Metabolism—ALDOB—esophageal cancer	1.27e-06	2.13e-05	CbGpPWpGaD
Docetaxel—ABCC1—Metabolism—PTGS2—esophageal cancer	1.26e-06	2.11e-05	CbGpPWpGaD
Docetaxel—ABCC1—Disease—EP300—esophageal cancer	1.25e-06	2.1e-05	CbGpPWpGaD
Docetaxel—ABCB1—Metabolism—CYP19A1—esophageal cancer	1.25e-06	2.1e-05	CbGpPWpGaD
Docetaxel—EGFR—Disease—CDKN1A—esophageal cancer	1.24e-06	2.08e-05	CbGpPWpGaD
Docetaxel—CYP3A4—Metabolism—GAPDH—esophageal cancer	1.22e-06	2.05e-05	CbGpPWpGaD
Docetaxel—CYP1B1—Metabolism—PTGS2—esophageal cancer	1.22e-06	2.04e-05	CbGpPWpGaD
Docetaxel—CYP3A4—Metabolism—CRABP1—esophageal cancer	1.21e-06	2.03e-05	CbGpPWpGaD
Docetaxel—EGFR—Signaling Pathways—CREBBP—esophageal cancer	1.21e-06	2.03e-05	CbGpPWpGaD
Docetaxel—ABCG2—Metabolism—NOS3—esophageal cancer	1.21e-06	2.03e-05	CbGpPWpGaD
Docetaxel—CYP3A7—Metabolism—NOS3—esophageal cancer	1.2e-06	2.01e-05	CbGpPWpGaD
Docetaxel—EGFR—Disease—EP300—esophageal cancer	1.18e-06	1.98e-05	CbGpPWpGaD
Docetaxel—CYP3A4—Metabolism—GNG7—esophageal cancer	1.15e-06	1.93e-05	CbGpPWpGaD
Docetaxel—ABCB1—Metabolism—HMOX1—esophageal cancer	1.14e-06	1.91e-05	CbGpPWpGaD
Docetaxel—ABCG2—Metabolism—PTGS2—esophageal cancer	1.11e-06	1.86e-05	CbGpPWpGaD
Docetaxel—CYP3A7—Metabolism—PTGS2—esophageal cancer	1.1e-06	1.84e-05	CbGpPWpGaD
Docetaxel—SLCO1B3—Metabolism—PIK3CA—esophageal cancer	1.1e-06	1.84e-05	CbGpPWpGaD
Docetaxel—ABCC1—Disease—MYC—esophageal cancer	1.09e-06	1.83e-05	CbGpPWpGaD
Docetaxel—EGFR—Signaling Pathways—NOS3—esophageal cancer	1.08e-06	1.82e-05	CbGpPWpGaD
Docetaxel—CYP3A4—Metabolism—ALDH2—esophageal cancer	1.08e-06	1.81e-05	CbGpPWpGaD
Docetaxel—ABCC1—Disease—EGFR—esophageal cancer	1.07e-06	1.79e-05	CbGpPWpGaD
Docetaxel—ABCC1—Metabolism—EP300—esophageal cancer	1.05e-06	1.76e-05	CbGpPWpGaD
Docetaxel—EGFR—Signaling by GPCR—PIK3CA—esophageal cancer	1.03e-06	1.73e-05	CbGpPWpGaD
Docetaxel—CYP3A4—Metabolism—GSTT1—esophageal cancer	1.03e-06	1.72e-05	CbGpPWpGaD
Docetaxel—EGFR—Disease—MYC—esophageal cancer	1.03e-06	1.72e-05	CbGpPWpGaD
Docetaxel—CYP3A4—Metabolism—CYP2A6—esophageal cancer	1.02e-06	1.7e-05	CbGpPWpGaD
Docetaxel—EGFR—Signaling Pathways—ERBB2—esophageal cancer	1.01e-06	1.7e-05	CbGpPWpGaD
Docetaxel—CYP1B1—Metabolism—EP300—esophageal cancer	1.01e-06	1.7e-05	CbGpPWpGaD
Docetaxel—CYP3A5—Metabolism—CREBBP—esophageal cancer	9.69e-07	1.63e-05	CbGpPWpGaD
Docetaxel—CYP3A4—Metabolism—ENO1—esophageal cancer	9.63e-07	1.62e-05	CbGpPWpGaD
Docetaxel—CYP3A4—Metabolism—PTGS1—esophageal cancer	9.63e-07	1.62e-05	CbGpPWpGaD
Docetaxel—CYP3A4—Metabolism—PSME2—esophageal cancer	9.49e-07	1.59e-05	CbGpPWpGaD
Docetaxel—CYP3A4—Metabolism—PSME1—esophageal cancer	9.49e-07	1.59e-05	CbGpPWpGaD
Docetaxel—EGFR—Immune System—PIK3CA—esophageal cancer	9.44e-07	1.58e-05	CbGpPWpGaD
Docetaxel—ABCC1—Disease—PIK3CA—esophageal cancer	9.25e-07	1.55e-05	CbGpPWpGaD
Docetaxel—ABCG2—Metabolism—EP300—esophageal cancer	9.21e-07	1.55e-05	CbGpPWpGaD
Docetaxel—CYP3A7—Metabolism—EP300—esophageal cancer	9.13e-07	1.53e-05	CbGpPWpGaD
Docetaxel—EGFR—Signaling Pathways—CCND1—esophageal cancer	8.97e-07	1.5e-05	CbGpPWpGaD
Docetaxel—EGFR—Disease—PIK3CA—esophageal cancer	8.72e-07	1.46e-05	CbGpPWpGaD
Docetaxel—CYP3A5—Metabolism—NOS3—esophageal cancer	8.68e-07	1.46e-05	CbGpPWpGaD
Docetaxel—EGFR—Signaling Pathways—CDKN1A—esophageal cancer	8.67e-07	1.45e-05	CbGpPWpGaD
Docetaxel—EGFR—Signaling Pathways—EP300—esophageal cancer	8.25e-07	1.38e-05	CbGpPWpGaD
Docetaxel—CYP3A4—Metabolism—CYP1B1—esophageal cancer	8.19e-07	1.37e-05	CbGpPWpGaD
Docetaxel—CYP3A5—Metabolism—PTGS2—esophageal cancer	7.94e-07	1.33e-05	CbGpPWpGaD
Docetaxel—ABCC1—Metabolism—PIK3CA—esophageal cancer	7.75e-07	1.3e-05	CbGpPWpGaD
Docetaxel—CYP3A4—Metabolism—CYP19A1—esophageal cancer	7.7e-07	1.29e-05	CbGpPWpGaD
Docetaxel—CYP1B1—Metabolism—PIK3CA—esophageal cancer	7.49e-07	1.26e-05	CbGpPWpGaD
Docetaxel—ABCB1—Metabolism—CREBBP—esophageal cancer	7.31e-07	1.23e-05	CbGpPWpGaD
Docetaxel—EGFR—Signaling Pathways—MYC—esophageal cancer	7.19e-07	1.21e-05	CbGpPWpGaD
Docetaxel—CYP3A4—Metabolism—HMOX1—esophageal cancer	7.02e-07	1.18e-05	CbGpPWpGaD
Docetaxel—ABCG2—Metabolism—PIK3CA—esophageal cancer	6.82e-07	1.14e-05	CbGpPWpGaD
Docetaxel—CYP3A7—Metabolism—PIK3CA—esophageal cancer	6.76e-07	1.13e-05	CbGpPWpGaD
Docetaxel—CYP3A4—Metabolism—ABCB1—esophageal cancer	6.74e-07	1.13e-05	CbGpPWpGaD
Docetaxel—CYP3A5—Metabolism—EP300—esophageal cancer	6.6e-07	1.11e-05	CbGpPWpGaD
Docetaxel—ABCB1—Metabolism—NOS3—esophageal cancer	6.55e-07	1.1e-05	CbGpPWpGaD
Docetaxel—EGFR—Signaling Pathways—PIK3CA—esophageal cancer	6.1e-07	1.02e-05	CbGpPWpGaD
Docetaxel—ABCB1—Metabolism—PTGS2—esophageal cancer	5.99e-07	1e-05	CbGpPWpGaD
Docetaxel—EGFR—Signaling Pathways—TP53—esophageal cancer	5.91e-07	9.91e-06	CbGpPWpGaD
Docetaxel—ABCB1—Metabolism—EP300—esophageal cancer	4.98e-07	8.36e-06	CbGpPWpGaD
Docetaxel—CYP3A5—Metabolism—PIK3CA—esophageal cancer	4.88e-07	8.19e-06	CbGpPWpGaD
Docetaxel—CYP3A4—Metabolism—CREBBP—esophageal cancer	4.51e-07	7.56e-06	CbGpPWpGaD
Docetaxel—CYP3A4—Metabolism—NOS3—esophageal cancer	4.03e-07	6.77e-06	CbGpPWpGaD
Docetaxel—CYP3A4—Metabolism—PTGS2—esophageal cancer	3.69e-07	6.19e-06	CbGpPWpGaD
Docetaxel—ABCB1—Metabolism—PIK3CA—esophageal cancer	3.68e-07	6.18e-06	CbGpPWpGaD
Docetaxel—CYP3A4—Metabolism—EP300—esophageal cancer	3.07e-07	5.15e-06	CbGpPWpGaD
Docetaxel—CYP3A4—Metabolism—PIK3CA—esophageal cancer	2.27e-07	3.81e-06	CbGpPWpGaD
